Summary
Gilead Sciences, Inc. (GILD) reported robust financial results for the second quarter and first half of 2008, driven by significant growth in its antiviral product sales, particularly Truvada and Atripla. Total revenues increased by 22% and 22% for the respective periods, reaching $1.28 billion and $2.54 billion. Net income also saw a healthy increase, up 9% and 15% to $442.8 million and $939.0 million, respectively. The company's strong operating performance is supported by increasing sales volumes and a favorable foreign currency exchange impact, although a decrease in royalty revenues from Tamiflu sales due to lower demand presented a headwind. Financially, Gilead maintained a strong liquidity position with over $2.9 billion in cash, cash equivalents, and marketable securities. The company continued its active share repurchase program, reflecting confidence in its financial health and shareholder returns. Management is also progressing on its R&D pipeline, with key advancements in its HIV and hepatitis C programs, alongside strategic acquisitions to bolster its portfolio. The company's substantial growth, coupled with a healthy balance sheet and ongoing pipeline development, positions it favorably.
Financial Highlights
28 data points| Revenue | $1.28B |
| Cost of Revenue | $265.68M |
| Gross Profit | $1.01B |
| SG&A Expenses | $219.53M |
| Operating Expenses | $672.61M |
| Operating Income | $605.51M |
| Interest Expense | $16.43M |
| Net Income | $434.78M |
| EPS (Basic) | $0.23 |
| EPS (Diluted) | $0.23 |
| Shares Outstanding (Basic) | 1.85B |
| Shares Outstanding (Diluted) | 1.93B |
Key Highlights
- 1Total revenues for Q2 2008 grew 22% year-over-year to $1.28 billion, and for the first six months of 2008, revenues increased 22% to $2.54 billion.
- 2Net income for Q2 2008 rose 9% to $442.8 million ($0.46 per diluted share), and for the first six months, it increased 15% to $939.0 million ($0.97 per diluted share).
- 3Product sales were a key driver, with total product sales increasing 34% in Q2 2008 to $1.22 billion, largely fueled by strong performance in antiviral products like Truvada and Atripla.
- 4The company maintained a strong liquidity position, with cash, cash equivalents, and marketable securities totaling $2.91 billion as of June 30, 2008.
- 5Gilead repurchased a significant amount of its common stock, with $965.8 million spent in the first six months of 2008, demonstrating a commitment to returning capital to shareholders.
- 6The company advanced its R&D pipeline, initiating Phase 3 trials for its novel HIV integrase inhibitor, elvitegravir, and continuing development for other promising candidates.
- 7Royalty revenues decreased significantly (63% in Q2) primarily due to lower Tamiflu sales reported by Roche, impacting overall revenue composition.